#Capital Markets #Liechtenstein #Vaduz #Implantica #RefluxStop

Implantica's Capital Markets Day: A Unique Insight into Medical Innovations

On September 9, 2026, Implantica AG successfully hosted its annual Capital Markets Day in Stockholm, gathering stakeholders, medical professionals, and media to discuss its innovative health technologies and strategies. This event is now available for viewing online, encompassing enlightening presentations from key figures in the medical field as well as insights into the company's future direction.

The highlight of the session was the detailed discussion on Implantica’s flagship product, RefluxStop®, which recently received FDA approval. This implantable device offers a groundbreaking approach to treating gastroesophageal reflux disease (GERD) by restoring the natural function of the lower esophageal sphincter (LES) without the common complications associated with traditional surgical methods.

A Platform for Discussion

The webcast was thoughtfully structured into several chapters, allowing attendees to navigate seamlessly between topics of interest. The presentations spanned various aspects, including the company’s vision and strategy, U.S. market opportunities, and marketing initiatives led by experts like Amit Kukreja (COO) and Juanita Eberhart (VP Marketing).

Dr. Peter Forsell, CEO and Founder, kicked off the event with a comprehensive update on the U.S. commercial strategy, expressing optimism about the opportunities ahead for RefluxStop® and emphasizing the significance of patient testimonials and physician insights. His upbeat tone reflected the growing confidence in the product's potential to alter the landscape of anti-reflux treatments.

Voices from the Medical Community

In addition to corporate strategies, the Capital Markets Day featured perspectives from leading surgeons, such as Dr. John C. Lipham from the University of Southern California, who discussed clinical experiences and future outlooks for the RefluxStop® procedure. Attendees were particularly moved by personal stories shared, including one from a surgeon who has benefited from the RefluxStop® device personally. This human element brought a relatable and emotional connection to the technological advancements being presented.

Other significant contributions came from Dr. J. Daniel Sánchez, who provided insights from Europe, and Dr. Ahmed Ahmed, who spoke about advancements in medical technology and patient care at the Imperial College Healthcare NHS Trust. Audience members had the opportunity to participate in an interactive Q&A session, engaging directly with the experts and addressing common concerns regarding the procedure's effectiveness and safety.

The Future of Implantable Technologies

Implantica aims to transform the standard of care with its innovative product pipeline extending beyond RefluxStop®. The company is also developing two platform technologies: an eHealth platform for monitoring and managing implants remotely and a wireless energizing platform designed to power implantable devices safely. These new initiatives underline the company’s dedication to furthering the intersection of technology and healthcare, enhancing patient outcomes while potentially reducing healthcare costs.

Attend the Webcast

For those who missed the live event, the recording is readily available on Implantica's website, segmented into chapters for easy access. This allows viewers to revisit the presentations, explore the insights shared, and stay updated on future innovations in the medical field.

Implantica AG continues to pave the way for advanced treatment solutions, striving to improve patient quality of life through innovative medical technologies. Those interested in exploring these initiatives and the promising future of RefluxStop® can watch the full webcast here. As the company moves forward, stakeholders remain optimistic about the potential impact these advancements may bring to GERD treatment protocols.